Ascletis Pharma Inc. has announced the dosing of the first participants in its U.S. Phase I clinical trial of ASC50, a potential best-in-class oral small molecule IL-17 inhibitor for the treatment of psoriasis. This trial is designed to assess the safety, tolerability, and preliminary efficacy of ASC50. Preclinical data, showing higher oral exposure, longer half-life, and strong efficacy, suggest ASC50 could be a leading once-daily oral treatment option for psoriasis. The trial is randomized, double-blind, and placebo-controlled, involving both healthy participants and patients with mild-to-moderate plaque psoriasis. The results of this study are expected to be presented in the future.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.